Form 8.5 (EPT/RI)-Amendment Advanced Medical Solutions

Investec Bank, acting as adviser and joint broker to Advanced Medical Solutions Group, disclosed net purchases of 272,009 ordinary shares on 17 September 2026. It bought 342,106 shares at 281.50p-281.75p and sold 70,097 shares at 281.75p under Takeover Code Rule 8.5. The filing reported no derivatives, options, indemnities or other dealing arrangements and is routine transaction disclosure rather than a change in offer terms.

Analysis

This is not directional institutional demand: exempt-principal-trader activity by a deal adviser is ordinarily client facilitation and/or temporary inventory management, not an Investec proprietary view on Advanced Medical Solutions (AMS.L). The narrow dealing range offers no evidence of a revised valuation anchor, competing-bid probability, or change in transaction terms. The practical implication is that any tape strength attributable to this flow should be treated as non-informational and potentially reversible once inventory is recycled.

For the next several days, the relevant risk is technical rather than fundamental: adviser-linked buying can reduce immediately available float and tighten the spread, but it should not support a durable premium absent a formal offer update, shareholder irrevocables, or a revised recommendation. Over 1-3 months, downside asymmetry remains tied to deal-break risk and the pre-offer standalone valuation; upside requires a competing bidder or higher consideration, neither of which is evidenced here. Do not use INVP as a proxy trade: Investec's disclosed role creates fee and balance-sheet exposure that is immaterial relative to its broader earnings base.

Contrarian takeaway: market participants often over-read Rule 8.5 purchases as informed accumulation. The disclosure explicitly identifies an intermediary capacity, making that interpretation weak. A meaningful signal would instead be persistent purchases by non-exempt funds, rising borrow costs, unusual call activity, or disclosed stakes from merger-arbitrage specialists.

Key Decisions for Investors

• No new directional position in AMS.L from this filing alone; classify as flow noise and reassess only on a Rule 2.7 firm-offer announcement, revised terms, or a non-exempt 1%+ stake disclosure.
• For an existing AMS.L merger-arbitrage long, retain only if the gross spread to indicated consideration remains sufficient for deal-break risk; reduce if the spread compresses solely on adviser-facilitation volume without confirmatory offer-process news.
• Set an alert for AMS.L closing materially above the disclosed dealing range on greater-than-normal volume. If not accompanied by a regulatory announcement or new stake disclosure within 1-2 sessions, view the move as a potential fade rather than evidence of bid upside.
• Avoid trading INVP on this event. Revisit only if a transaction outcome creates a quantifiable fee, underwriting, or capital-commitment disclosure large enough to affect consensus earnings.